// App-Quantinova.ai

1510 : Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis

Researchers

Presenter

  • Philip Mease

Principal Investigators

  • Proton Rahman

  • Victoria Navarro-Compan

  • Vibeke Strand

  • Theresa Hunter

  • David Sandoval

  • Jeffrey Lisse

  • Fangyi Zhao

  • Helena Marzo-Ortega

Medical Centers

  • Oregon Health and Science University, Portland, OR

  • Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

  • Memorial University, Newfoundland, Canada

  • University Hospital La Paz, Madrid, Spain

  • Division of Hematology, Stanford University, Stanford, CA

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, Indianapolis, IN

  • NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, University of Leeds, Leeds, Leeds, United Kingdom

Locations

  • United States

  • Canada

  • Spain

  • United Kingdom

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Axial spondyloarthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • Adalimumab

  • LY2439821

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved